Empirical evidence for the use of lithium and anticonvulsants in children with psychiatric disorders.

Department of Psychiatry, Harvard Medical School, USA.
Harvard Review of Psychiatry (Impact Factor: 2.49). 01/2006; 14(6):285-304. DOI: 10.1080/10673220601082869
Source: PubMed

ABSTRACT The use of psychotropic medications-in particular, mood stabilizers--in youths with psychiatric illness has grown. There are trends toward polypharmacy and the increased use of newer mood stabilizers in youths with psychiatric illness despite a paucity of studies examining the short- and long-term efficacy and safety of these agents in the pediatric population.
PubMed was used to identify peer-reviewed publications from the past 30 years (January 1975 to August 2005) studying lithium and anticonvulsants in youths with psychiatric illness.
Evidence supporting the use of lithium and valproate in the treatment of juvenile bipolar disorder and reactive aggression has grown. Evidence for the use of other anticonvulsants in youths with psychiatric illness is sparse. Side effects from lithium and anticonvulsants are typically mild to moderate. Data are accumulating in regard to the longer-term safety of lithium and DVPX in the juvenile psychiatric population. Although data in regard to the newer anticonvulsants are limited, they may have more desirable side-effect profiles.
Double-blind, placebo-controlled trials of lithium and anticonvulsants are greatly needed as clinical use of these agents has risen without sufficient evidence supporting their efficacy in the pediatric population.

Download full-text


Available from: Melissa Lopez-Larson, Sep 02, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mood stabilizers and anticonvulsants have been frequently used to control behaviors in children and adolescent with nonaffective disorders. The purpose of this study was to review the literature to evaluate the evidence of these agents as treatment options in this subset of patients. We reviewed all the literature between 1949 and 2009 on the use of anticonvulsants and mood stabilizers in controlling severe behavior dysregulation and aggression in child and adolescent who do not meet the criteria for any mood disorder. The review revealed a total of 19 studies. Of the different mood stabilizers/anticonvulsants, both lithium and divalproex showed some promise in treating children and adolescents with nonmood disorders. Larger studies are nevertheless needed to support the ongoing use of these current anticonvulsants and mood stabilizers in children and adolescents with nonmood disorders. Also, further investigation to the potential use in the long term would need to be established, bearing in mind the balance of side effects and treatment benefit.
    Clinical neuropharmacology 01/2010; 33(6):303-11. DOI:10.1097/WNF.0b013e3181f8d4ed · 1.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The current retrospective study examined the treatment effectiveness of a residential treatment center (RTC) for adolescent males using a psychotropic medication reduction protocol. Of 226 participants 64% were admitted on medication, with 69% of those on multiple medications. At admission, those on medication endorsed more emotional and behavioral symptoms. Those admitted without medication had better program compliance. Two-thirds of those admitted on medication had all medications discontinued. The majority remaining on medication had a decrease in number of medications. At discharge and follow up periods, all participants, regardless of medication status, generally fared equally, lending support for the RTC program and its use of the medication protocol. Implications and suggestions for future research are included.
Show more